Aa
New treatment drugs
My doc expects telaprivir in clinic late 2011 / early 2012.
Emerging Treatments for Hepatitis C
Those of you who are facing the challenge of hepatitis C should be optimistic – there are now several new treatments with proven activity against hepatitis C and over 20 of these treatments are being tested. The process for getting a drug tested and put on the market for use takes several years. Peginterferon/ribavirin (PEG/RBV) is the current standard of care for treatment of chronic hepatitis C.
Here is a overview of the new emerging drugs .
New Interferons
•
Albuferon is a new long‐acting interferon only requires dosing is every 2 weeks, as opposed to every week dosing characteristic of the peginterferons. Rates of cure or virologic response, and side effects are similar to peginterferons.
•
Lambda Interferon is a new type of pegylated interferon (type III) – early studies indicate that it has activity against HCV. Current studies suggest less side effects, and less reduction in blood cell counts compared to the currently used type I (alfa) peginterferons.
•
Other interferons being studied include Locteron, Belerofon, Oral Interferon, and Omega Interferon
•
Viramidine (Taribavirin) is a substitute for ribavirin that is being tested.
Protease Inhibitors
•
Telaprevir (TPV) looks encouraging with more people responding and a shorter period of treatment time being tested.
•
Boceprevir (BPV) looks encouraging when added to Peg Interferon and Ribavirin.
•
Other protease inhibitors under study include ACH‐1625, ABT‐450 HCV, BI 201335, VX‐813, PHX1766, VX‐500, ITMN‐191 (R‐7227), MK7009, SCH900518, and TMC435.
Polymerase Inhibitors
•
R7128 is furthest in development and currently the most promising – it has been studied with PEG/RBV and is active against all HCV genotypes.
•
Other polymerase inhibitors under study include MK‐3281, PSI‐7851, IDX‐184, ANA‐598, ABT‐333, VCH‐916, PF‐00868554, BI 207127, GS‐9190, and VCH‐759.
•
NS5A Inhibitor is very active against HCV and is entering Phase 2 studies with PEG/RBV.
Other Approaches
•
Nitazoxanide (Alinia) is being tested in the US to determine if it is active against genotype 1 HCV.
•
Cyclophyllin Inhibitors are compounds related to cyclosporine chemically but with better activity against HCV.
•
Therapeutic Vaccines. One of the most successful of these vaccines, was developed here in Colorado by GlobeImmune – GI‐5005. It is demonstrating activity when given with PEG/RBV. Others under study include ChronVac‐C, TG4040, PeviPROTM, HCV/MF59, and IC41.
New drugs for treatment of HCV will likely reach the clinic by the end of 2011 or beginning of 2012. They will be given in addition to the current PEG/RBV. Given the potential treatment options, it would not be surprising, that within 5 to 10 years nearly every patient with HCV could be effectively treated!
Emerging Treatments for Hepatitis C
Those of you who are facing the challenge of hepatitis C should be optimistic – there are now several new treatments with proven activity against hepatitis C and over 20 of these treatments are being tested. The process for getting a drug tested and put on the market for use takes several years. Peginterferon/ribavirin (PEG/RBV) is the current standard of care for treatment of chronic hepatitis C.
Here is a overview of the new emerging drugs .
New Interferons
•
Albuferon is a new long‐acting interferon only requires dosing is every 2 weeks, as opposed to every week dosing characteristic of the peginterferons. Rates of cure or virologic response, and side effects are similar to peginterferons.
•
Lambda Interferon is a new type of pegylated interferon (type III) – early studies indicate that it has activity against HCV. Current studies suggest less side effects, and less reduction in blood cell counts compared to the currently used type I (alfa) peginterferons.
•
Other interferons being studied include Locteron, Belerofon, Oral Interferon, and Omega Interferon
•
Viramidine (Taribavirin) is a substitute for ribavirin that is being tested.
Protease Inhibitors
•
Telaprevir (TPV) looks encouraging with more people responding and a shorter period of treatment time being tested.
•
Boceprevir (BPV) looks encouraging when added to Peg Interferon and Ribavirin.
•
Other protease inhibitors under study include ACH‐1625, ABT‐450 HCV, BI 201335, VX‐813, PHX1766, VX‐500, ITMN‐191 (R‐7227), MK7009, SCH900518, and TMC435.
Polymerase Inhibitors
•
R7128 is furthest in development and currently the most promising – it has been studied with PEG/RBV and is active against all HCV genotypes.
•
Other polymerase inhibitors under study include MK‐3281, PSI‐7851, IDX‐184, ANA‐598, ABT‐333, VCH‐916, PF‐00868554, BI 207127, GS‐9190, and VCH‐759.
•
NS5A Inhibitor is very active against HCV and is entering Phase 2 studies with PEG/RBV.
Other Approaches
•
Nitazoxanide (Alinia) is being tested in the US to determine if it is active against genotype 1 HCV.
•
Cyclophyllin Inhibitors are compounds related to cyclosporine chemically but with better activity against HCV.
•
Therapeutic Vaccines. One of the most successful of these vaccines, was developed here in Colorado by GlobeImmune – GI‐5005. It is demonstrating activity when given with PEG/RBV. Others under study include ChronVac‐C, TG4040, PeviPROTM, HCV/MF59, and IC41.
New drugs for treatment of HCV will likely reach the clinic by the end of 2011 or beginning of 2012. They will be given in addition to the current PEG/RBV. Given the potential treatment options, it would not be surprising, that within 5 to 10 years nearly every patient with HCV could be effectively treated!
Thanks for this heads up. Great to see it all listed.
Did you see Sidney Crosby's goal on Sunday? Thought I'd SVR'd only to have a heart attack.
Did you see Sidney Crosby's goal on Sunday? Thought I'd SVR'd only to have a heart attack.
IFN/Riba is no longer a choice for me so I try keeping up with new investigational drugs but its almost impossible to do these days there are so many being developed. What a good problem to have. I know your situation and some of these drugs may be the answer for those who are in the hard-to-treat population such as yourself. I'm pre-tp and would like nothing better than to clear before the big day comes if I can. Monotherapy would be very nice. There were some who actually svr'ed in the PI trials with monotherapy so its not an impossible outcome.
regards,
ML
regards,
ML
Hi Mr Liver,
Thank you for your answer, I've been diagnosed stage 3, slow progressive (I dont understand that but, ...), Have been treated, without success. Now I am waiting for new medicine, genotype offcourse, 1 (dont know subtype).
Lolak,
Thank you for your answer, I've been diagnosed stage 3, slow progressive (I dont understand that but, ...), Have been treated, without success. Now I am waiting for new medicine, genotype offcourse, 1 (dont know subtype).
Lolak,
Hi Diamondo,
The rate of fibrotic progression in any one individual is dependent upon numerous known factors and for the vast majority it will be a disease that progresses very slowly, rarely resulting in death. After all, it is not in any parasite's best interest to kill its host.
Two of the main factors which influence fibrotic progression are inflammation and the length of infection. As an example if you have been infected for 20 years and are scored an F1 and your liver enzymes are not excessively high upon repeated blood draws or through biopsy then you would be classified as a slow fibroser . A person such as this would probably not find it necessary to treat--ever.
There are some new studies out that I haven't read yet that uses over 30,000 cases to arrive at what is being called a "much more precise view" of fibrotic progression. If you search PubMed you will find alot of research on the topic with much of it by Thierry Poynard. I hope this helps some.regards,
ML
The rate of fibrotic progression in any one individual is dependent upon numerous known factors and for the vast majority it will be a disease that progresses very slowly, rarely resulting in death. After all, it is not in any parasite's best interest to kill its host.
Two of the main factors which influence fibrotic progression are inflammation and the length of infection. As an example if you have been infected for 20 years and are scored an F1 and your liver enzymes are not excessively high upon repeated blood draws or through biopsy then you would be classified as a slow fibroser . A person such as this would probably not find it necessary to treat--ever.
There are some new studies out that I haven't read yet that uses over 30,000 cases to arrive at what is being called a "much more precise view" of fibrotic progression. If you search PubMed you will find alot of research on the topic with much of it by Thierry Poynard. I hope this helps some.regards,
ML
Hi Mr Liver,
Thank you also from me for such expanded report, this is the subject, that all of us need to know.
DOes anyone know, how many years it takes to go from one stage of liver to another, for example, from stage 2 to stage 3, or from stage 3- further, etc... Or maybe that depends on the person?
Thank you in advance!
Thank you also from me for such expanded report, this is the subject, that all of us need to know.
DOes anyone know, how many years it takes to go from one stage of liver to another, for example, from stage 2 to stage 3, or from stage 3- further, etc... Or maybe that depends on the person?
Thank you in advance!
Great post getting it all together! Thanks.
I am optimistic about ACH-1625. It appears to be completely safe and reduced viral load nearly 4 log with only 5 days of monotherapy. Phase I trials were favorable and the drug has entered Phase II trials.
I am optimistic about ACH-1625. It appears to be completely safe and reduced viral load nearly 4 log with only 5 days of monotherapy. Phase I trials were favorable and the drug has entered Phase II trials.
Hi,
I don`t know much about the drug,other than what the doctor told me.She said they are getting a 80 percent svr.I will post any progress or if no progress I will post that too.I think the clinical trial is university funded but I am not sure.If you can find anymore information about this drug I would be interested to learn more about it.
Take care
I don`t know much about the drug,other than what the doctor told me.She said they are getting a 80 percent svr.I will post any progress or if no progress I will post that too.I think the clinical trial is university funded but I am not sure.If you can find anymore information about this drug I would be interested to learn more about it.
Take care
Hi
Thanks for your reply.
I had not heard of it (R05024048) until now. A quick lookaround on the net found very little info concerning this drug and nothing recent at that. Tell me more about it, if you know. Also, if you know, is this a corporate, university, or NIH funded study ?ML
Thanks for your reply.
I had not heard of it (R05024048) until now. A quick lookaround on the net found very little info concerning this drug and nothing recent at that. Tell me more about it, if you know. Also, if you know, is this a corporate, university, or NIH funded study ?ML
I am starting Jan.21 on a new drug called r05024048.Have you heard of it?It is made by Raush.
Great synopsis, thanks for that!!
I would add one other promising vaccine developing in phase 2 now by Inovio in Sweden.
97-99% of virus wiped out with this eletroporation infusion method in early studies, this method could make treatment then a basic mop up, and might allow for much lower dosing perhaps and shorter treatments as well.
mb
I would add one other promising vaccine developing in phase 2 now by Inovio in Sweden.
97-99% of virus wiped out with this eletroporation infusion method in early studies, this method could make treatment then a basic mop up, and might allow for much lower dosing perhaps and shorter treatments as well.
mb
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
